P21
CNTF-Derived Neurogenic Peptide
01
Overview
P21 is a synthetic peptide derived from Ciliary Neurotrophic Factor (CNTF), engineered to retain the neurotrophic signaling benefits of the parent protein while eliminating its associated inflammatory and cachectic side effects. Research focuses on its potential to stimulate neurogenesis, enhance synaptic plasticity, and support cognitive recovery in neurodegenerative contexts.
02
Mechanism of Action
P21 activates the JAK/STAT3 and MAPK/ERK signaling cascades downstream of the CNTF receptor complex (gp130/LIFRβ), promoting neuronal survival and differentiation. Unlike full-length CNTF, the peptide fragment does not trigger the cachectic response mediated by hypothalamic gp130 signaling, allowing selective neurotrophic activation.
03
Research Highlights
Preclinical studies demonstrate increased BrdU-positive cells in the hippocampal dentate gyrus
Spinal cord injury models show enhanced motor neuron survival and functional recovery
Comparative studies confirm neurotrophic activity without CNTF-associated weight loss in animal models
04
Dosage
Administration & Timing
Subcutaneous (SC) injection into abdominal or gluteal subcutaneous tissue or intranasal. Research protocols use once-daily administration; timing independent of food.
Dosage Guidelines
Cycle Length
2–4 weeks; research is preclinical and long-term data is limited.
05
Reconstitution
Solvent
Bacteriostatic Water (0.9% benzyl alcohol)
Volume
2 mL added to a 10 mg vial
Concentration
5 mg/mL
Storage
Lyophilized powder: store at -20 °C long-term. Reconstituted: refrigerate 2–8 °C, use within 30 days.
Notes
P21 is a CNTF-derived peptide; research-stage with limited human exposure data.
Research Reference Only
Dosage and reconstitution values reflect commonly cited ranges from published research literature and are presented for educational and research reference only. This is not medical advice or a dosing recommendation. HEXAGEN does not endorse human use of any compound. Always consult a qualified healthcare professional.
Research Disclaimer
P21 is for educational and research purposes only. Not intended as medical advice. Consult a qualified healthcare professional before making any health-related decisions.
Related Compounds
View All
P21 Knowledge Graph
Explore how P21 connects to mechanisms, research goals, related compounds, research stacks, and scientific references. Drag nodes, zoom, and filter by type.
No nodes match the active filters.
P21 — Common Research Questions
What is P21?
P21 is a synthetic peptide derived from Ciliary Neurotrophic Factor (CNTF), engineered to retain the neurotrophic signaling benefits of the parent protein while eliminating its associated inflammatory... P21 belongs to the Cognitive research category and is studied for its cntf-derived neurogenic peptide.
How does P21 work?
P21 activates the JAK/STAT3 and MAPK/ERK signaling cascades downstream of the CNTF receptor complex (gp130/LIFRβ), promoting neuronal survival and differentiation. Unlike full-length CNTF, the peptide fragment does not trigger the cachectic response mediated by hypothalamic gp130 signaling, allowing selective neurotrophic activation.
What are the key research benefits of P21?
Neurogenesis stimulation via CNTF pathway activation. Synaptic plasticity and dendritic spine density enhancement. Neuroprotective effects in neurodegenerative research models. Cognitive recovery support after brain injury. Memory consolidation and learning enhancement. Avoids inflammatory side effects of full CNTF.
What is the molecular structure of P21?
P21 is a research compound in the Cognitive category. Detailed molecular structure data is being compiled. Refer to primary literature for structural analysis.
What does the research say about P21?
Preclinical studies demonstrate increased BrdU-positive cells in the hippocampal dentate gyrus Spinal cord injury models show enhanced motor neuron survival and functional recovery Comparative studies confirm neurotrophic activity without CNTF-associated weight loss in animal models These findings are based on preclinical and clinical research. P21 is a research compound and these studies do not constitute medical advice.
Is P21 FDA approved?
No. P21 is not FDA-approved for any indication. It is a research chemical studied in preclinical and early clinical research. These compounds are not approved for human therapeutic use and should only be studied in appropriate research settings.
What category does P21 belong to?
P21 belongs to the Cognitive category, which focuses on peptides investigated for their nootropic and neuroprotective potential, supporting mental clarity, memory consolidation, and neurological resilience. You can explore more compounds in this category on the Cognitive pillar page.
Related Articles
Semax: BDNF Upregulation and Cognitive Enhancement
A review of Semax's mechanism — from melanocortin receptor modulation to BDNF and NGF upregulation in the hippocampus.
Dihexa: Synaptogenesis and Spatial Memory
Washington State University research on Dihexa's dramatic effects on synaptogenesis and Morris water maze performance.
Noopept: The Dipeptide Nootropic
Understanding Noopept's prodrug conversion, BDNF/NGF upregulation, and its position as a dipeptide nootropic.
Scientific References
Preclinical studies demonstrate increased BrdU-positive cells in the hippocampal dentate gyrus
Spinal cord injury models show enhanced motor neuron survival and functional recovery
Comparative studies confirm neurotrophic activity without CNTF-associated weight loss in animal models